|
FDA WILL EXERCISE DISCRETION ON NDA, ANDA CHANGES
Drugmakers that submit, via an annual report, postapproval manufacturing changes made to comply with an official compendium will not face FDA enforcement action, the agency announced in a guidance document. This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives